Trials / Completed
CompletedNCT01358019
A Study of LY2523355 in Patients With Solid Cancer
A Phase 1 Study of LY2523355 in Patients With Solid Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to examine a recommended dose for subsequent phase trial(s), by the observation of the safety and toxicity profiles of LY2523355 in patients with advanced and/or metastatic cancer. The secondary objectives are to study the pharmacokinetics and antitumor effect.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2523355 | Days 1, 2, and 3 in a cycle that consists of 21-days |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2013-01-01
- Completion
- 2013-01-01
- First posted
- 2011-05-23
- Last updated
- 2013-01-28
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01358019. Inclusion in this directory is not an endorsement.